home / stock / hepa / hepa news

HEPA News and Press, Hepion Pharmaceuticals Inc. From 05/23/23

Stock Information
Company Name: Hepion Pharmaceuticals Inc.
Stock Symbol: HEPA
Market: NASDAQ
Website: hepionpharma.com
Menu
HEPA HEPA Quote HEPA Short HEPA News HEPA Articles HEPA Message Board
Get HEPA Alerts

News, Short Squeeze, Breakout and More Instantly...
HEPA - ARVL, MNK and MVST are among pre market losers

2023-05-23 08:45:00 ET Biocept ( BIOC ) 10% . Microvast Holdings ( MVST ) -20% plunges as Energy Department said to cancel DoE contract. Wave Life Sciences  ( WVE ) -13% crashes on decision to drop neurology asset on trial setback. ToughBuilt I...
HEPA - HEPA stock price surged but beware of this glaring Hepion risk

2023-05-23 05:02:33 ET Hepion Pharmaceuticals’ ( NASDAQ: HEPA ) stock price went parabolic on Monday after the company made an important announcement about its mid-stage trial. The shares jumpd by more than 110% and reached a high of $19.66, the highest level since January 17...

HEPA - Microbot Medical, Hepion Pharmaceuticals among healthcare gainers; Rain Oncology leads losers

2023-05-22 10:03:29 ET Gainers: Microbot Medical ( MBOT ) +46% . Hepion Pharmaceuticals ( HEPA ) +41% . Atea Pharmaceuticals ( AVIR ) +38% . VectivBio Holding ( VECT ) +37% . CNS Pharmaceuticals ( CNSP ) +23% . Losers: Rain Oncology ( ...

HEPA - Hepion Pharma NASH candidate meets phase 2 goal; up 68%

2023-05-22 07:43:13 ET Hepion Pharmaceuticals' ( NASDAQ: HEPA ) non-alcoholic steatohepatitis ( NASH ) candidate rencofilstat met primary and secondary endpoints in a mid-stage trial. The microcap is up ~68% in Monday premarket trading. Data from the ALTITUDE-NASH ...
HEPA - Hepion Pharmaceuticals' Phase 2 'ALTITUDE-NASH' Trial Achieves Primary and Secondary Endpoints, Including Improvement in Liver Function and Multiple NASH Biomarkers

- Improvements in physiologic liver function and key NASH biomarkers including ALT, ProC3, PIIINP and ELF - - Results reinforce rencofilstat’s direct antifibrotic mode of action; increases confidence for reductions in fibrosis in ongoing Phase 2b ‘ASCEND-NASH’ paire...

HEPA - Hepion Pharmaceuticals Schedules Conference Call to Review Topline Results from Phase 2 'ALTITUDE-NASH' Liver Function Trial of Rencofilstat

EDISON, N.J., May 19, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of fibrotic diseases, including non-alcoholic steatoh...

HEPA - Organogenesis, Arcturus top healthcare gainers; ImmunityBio, Dynatronics among losers

2023-05-11 10:00:13 ET Gainers: Organogenesis ( ORGO ) +23% . Arcturus Therapeutics ( ARCT ) +14% . Phathom Pharmaceuticals ( PHAT ) +14% . Pulse Biosciences ( PLSE ) +13% . PharmaCyte Biotech ( PMCB ) +11% . Losers: ImmunityBi...
HEPA - Hepion Pharmaceuticals, Inc. Announces Reverse Stock Split

EDISON, N.J., May 10, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of fibrotic diseases, including non-alcoholic steatoh...

HEPA - Hepion Pharmaceuticals to Present Data on Synergistic Effects of Rencofilstat with Anti-PD1 at AACR 2023

EDISON, N.J., April 17, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of fibrotic diseases, including non-alcoholic steat...

HEPA - Hepion Pharmaceuticals Expands SAB with Appointments of Four Liver Disease KOLs

EDISON, N.J., March 30, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of fibrotic diseases, including non-alcoholic steat...
Previous 10 Next 10